Clinical trial
Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage…
NCT00130260 · Nabi Biopharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00130260 |
|---|---|
| Title | Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease |
| Official title | Phase 3b Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating Immunogenicity and Safety of a 3rd and 4th Dose of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Adults With End-Stage Renal Disease |
| Acronym | SHIELD-2 |
| Lead sponsor | Nabi Biopharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Staphylococcal Infections, Chronic Kidney Failure |
| Intervention type | Biological |
| Interventions | Staph aureus types 5 and 8 conjugate vaccine, placebo |
| Enrollment | 99 |
| Start date | Aug 1, 2005 |
| Primary completion | Dec 1, 2005 |
| Completion | Apr 1, 2006 |
| First posted | Aug 15, 2005 |
| Last update posted | Jan 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: